# Regeneron AA Multicenter (Dupilumab)

> **NCT05551793** · PHASE2 · RECRUITING · sponsor: **Emma Guttman** · enrollment: 68 (estimated)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05551793
- **Lead sponsor:** Emma Guttman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-10
- **Primary completion:** 2027-11-03
- **Final completion:** 2027-11-03
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551793, "Regeneron AA Multicenter (Dupilumab)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05551793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*